AI De Novo Protein Platform

The ground-breaking LuxSit™ Pro, de novo binders, and the biosensors that Monod Bio is developing are based on a dramatically expanded development space enabled by our AI-powered de novo protein design platform. Monod Bio is at the forefront of using AI de novo protein design for the development of new research use only (RUO) tools and in vitro diagnostics (IVD) for use in the central lab and point-of-care (POC) settings.

Binders

Monod Bio is developing de novo protein binders that provide for sensitive detection of proteins, peptides, and small molecules. These binders enable multiple RUO and IVD applications for high-value targets. These de novo binders are small and highly stable and require no post-translational modifications.

They may also be functionalized with enzymes, fluorescent probes, chemi- or bio-luminescent probes, or site specific surface chemistry.

Reporters

LuxSit™ Pro is the world’s first fully de novo luciferase.

The Monod Bio LuxSit™ Pro family of products are the world’s smallest and highest performance de novo luciferases available on the market. They are available in multiple formats for various applications, including full length protein reporters, or the complementation system ideal for revealing protein-protein interactions.The commercial kits include the LuxSit™ Pro enzyme, as well as a proprietary substrate and buffer. These provide for optimized brightness and glow time for in vitro assays.

Biosensors

Monod Bio has created a novel AI/ML protein design platform to create novel protein biosensors. These protein tools are optimal for bioluminescent homogeneous assays that are quantitative, no-wash single-step, fast (<5 min) and use inexpensive reagents.

Commonly available laboratory equipment can be used to quantify the reporter signal.